Company profile
Company profile
The strategy
Corporate history
Print page
Send page
Save page
Bookmark page
STADA as homepage
Company profile
STADA - Corporate history
The most important milestones in the company’s history:
2010
- Market capitalization on June 30, 2010: EUR 1.61 billion / Enterprise value: approx: EUR 2.5 billion
2009
- Market capitalization on December 31, 2009: EUR 1.42 billion / Enterprise value: approx: EUR 2.3 billion
2008
- Sales at record level for the thirteenth time in a row
- Market capitalization on December 31, 2008: EUR 1.20 billion / Enterprise value: approx: EUR 2,2 billion
2007
- Acquisition of the British Forum Bioscience group
- Acquisition of the Russian MAKIZ group
2006
- Acquisition of the Serbian Hemofarm Group
- Sale of US subsidiary
2005
- Acquisition of a package of eleven European branded products (amongst others Mobilat®)
- STADA acquired a 58% stake in the Chinese pharmaceuticals manufacturing company BCP
- Acquisition of the Portuguese generics supplier Ciclum Farma
- Acquisition of approx. 97.5% of the shares in the Russian pharmaceuticals company, Nizhpharm
2004
- Acquisition of a portfolio of Branded Products in Italy
- De facto 1:1 stock split
- Early Entry Mirtazapine
2003
- Capital measures raised total net funds of EUR 256.4 million
- Acquisition of a package of branded products from redinomedica, for the German OTC market
- Acquisition of UK generics supplier Schein Pharmaceuticals with generics sales line Genus
- Acquisition of 60% stake in Italy’s NPA, a sales specialist in the pharmacy sector
- For the first time: Market capitalization > EUR 1 billion
2002
- Start of operations in the USA with the sales company STADA Pharmaceuticals Inc. after acquiring the business of the US generics supplier MOVA Laboratories
- Acquisition of marketing and sales activities of Italian pharmaceutical company Crinos
- Acquisition of Spanish generics supplier Bayvit S.A.
- STADA increases stake in Spanish brand supplier Ciclum Farma to 100%
- Acquisition of numerous local branded products
- Conversion from German accounting standards (HGB) to IAS
- Inclusion in EuroSTOXX 600 stock index
2001
- Sales exceed the EUR 500 million threshold
- Conversion of preferred shares into registered common shares
- STADA common stock is included in the German mid-cap index, MDAX
- Majority investments in the Philippines (Croma Medic Ltd.)
- Start-up of biogenerics cooperation with DSM, utilizing private venture capital
2000
- Stock split 1:10 for common and preferred stock
- Acquisition of Clonmel Healthcare Ltd., the leader in the Irish generics market
1999
- Start-up of STADA Asiatic Co. Ltd., Bangkok
- Investment in Spain in Ciclum Farma, Madrid
- Start-up in Italy with EG S.p.A., Milan
1998
- Conclusion of the process of going public with registered common stock
- Acquisition in Denmark (PharmaCoDane Aps)
- Positioning as comprehensive supplier in the health care market with the acquisition of oncologics (cell pharm) and a package of discretionary prescription brands from Fresenius
1997
- Beginning of process of going public with non-voting preferred stock
1996
- Purchase of ALIUD PHARMA as second generics line in Germany
- Expansion into France (EG Laboratoires EuroGenerics S.A.) and the Czech Republic (ALIUD PHARMA CZ s.r.o.)
1995
- Expansion of the STADA Group structure with market-oriented sales companies
1992
- Start-up in Asia with STADA Pharmaceuticals (Asia) Ltd. in Hong Kong
1991
- Acquisitions in the Netherlands (Centrafarm B.V.) and in Belgium (N.V. Eurogenerics S.A.)
1986
- Beginning of internationalization (Helvepharm AG/Switzerland, STADA Arzneimittel/Austria)
1975
- Entry into the emerging generics market
1970
- STADA becomes a stock corporation with registered shares exclusively for pharmacists
1956
- Move to the present location in Bad Vilbel
1948
- New beginning at the locations in Essen and Tübingen with products for self-medication
1895
- Founded in Dresden as a pharmacists’ cooperative
 |
